SMR - The reality of artificial intelligence in drug discovery

Artificial Intelligence is constantly in the news, with applications from self-driving cars, healthcare, share-trading, and law. There are also many applications in drug discovery and development, and the promise of the field has led to the formation of many new AI companies, formation of AI groups at large pharma and significant financial investment in the field. Automated drug design, drug repurposing and retrosynthesis are just a few of the specific application areas of AI. But how does the reality match the hype. The meeting brings together recognised experts to provide a realistic view and discuss the likely future of AI in Drug Discovery.

Speakers include:

• Pat Walters – SVP Computation, Relay Therapeutics
• Hugo Ceulemans - Scientific Director, Discovery Data Sciences, Janssen Pharmaceuticals
• Quentin Perron - CSO, Iktos
• Lucy Colwell - Lecturer in Molecular Informatics, Unilever Cambridge Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge
• Frank Von Delft – Professor of Structural Chemical Biology, Nuffield Dept of Medicine and Structural Genomics Consortium, University of Oxford
• Phil Judson – Director and consultant, Lhasa, Leeds
• Alpha Lee - CoFounder of PostEra, Cambridge